Ross Stewart

5.1k total citations · 2 hit papers
46 papers, 2.4k citations indexed

About

Ross Stewart is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ross Stewart has authored 46 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 14 papers in Immunology and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ross Stewart's work include Cancer Immunotherapy and Biomarkers (23 papers), Immunotherapy and Immune Responses (8 papers) and PARP inhibition in cancer therapy (7 papers). Ross Stewart is often cited by papers focused on Cancer Immunotherapy and Biomarkers (23 papers), Immunotherapy and Immune Responses (8 papers) and PARP inhibition in cancer therapy (7 papers). Ross Stewart collaborates with scholars based in United Kingdom, United States and South Korea. Ross Stewart's co-authors include Robert W. Wilkinson, Michelle Morrow, Edmund Poon, Simon J. Dovedi, Jamie Honeychurch, Tim Illidge, Eleanor J. Cheadle, Grazyna Lipowska‐Bhalla, Amy L. Adlard and Ian J. Stratford and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Ross Stewart

44 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade

2014 974 citations Simon J. Dovedi, Amy L. Adlard et al. Cancer Research profile →
Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial

2021 160 citations Bradley J. Monk, Nicoletta Colombo et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Ross Stewart

Since Specialization

Citations

This map shows the geographic impact of Ross Stewart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ross Stewart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ross Stewart more than expected).

Fields of papers citing papers by Ross Stewart

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ross Stewart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ross Stewart. The network helps show where Ross Stewart may publish in the future.

Co-authorship network of co-authors of Ross Stewart

This figure shows the co-authorship network connecting the top 25 collaborators of Ross Stewart. A scholar is included among the top collaborators of Ross Stewart based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ross Stewart. Ross Stewart is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pretrained transformers applied to clinical studies improve predictions of treatment efficacy and associated biomarkers 2025 ·Nature Communications ·Gustavo Arango-Argoty, (unknown), Ross Stewart, Gerald J. Sun, (unknown), Ioannis Kagiampakis, Etai Jacob	7
2	555MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment (tx) for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Final results from the phase Ib/II BEGONIA study 2025 ·Annals of Oncology ·Peter Schmid, Hao‐Chien Wang, (unknown), Y.H. Park, X. Cynthia, (unknown), S.C. Chen, (unknown), Catherine Prady, L-M Tseng, Jamil Asselah, Piotr J. Wysocki, Simon Lord, (unknown), Ross Stewart, (unknown), (unknown), S-A. Im	1
3	Abstract PO1-19-10: Durvalumab + datopotamab deruxtecan in patients with PD-L1 positive advanced/metastatic triple-negative breast cancer: Arm 8 of the phase 1b/2, open label, platform BEGONIA study 2024 ·Cancer Research ·Peter Schmid, X. Cynthia, (unknown), Ross Stewart, Katrin Heider, (unknown), Neelima Denduluri	1
4	Abstract 7617: Quantitative continuous scoring of PD-L1 for superior patient selection for anti-PD-L1 treatment of locally advanced or unresectable NSCLC 2024 ·Cancer Research ·(unknown), (unknown), Simon Christ, (unknown), Thomas Padel, Laura Sebastián Monasor, (unknown), Tze Heng Tan, Daša Medříková, (unknown), Anatoliy Shumilov, Hadassah Sade, Günter Schmidt, Ross Stewart, Yashaswi Shrestha	1
5	Abstract 2492: Enhanced patient selection for anti-PD-L1 treatment in metastatic NSCLC with quantitative continuous scoring of PD-L1 2024 ·Cancer Research ·(unknown), Markus Schick, Thomas Kunzke, Federico Pollastri, (unknown), Harald Hessel, (unknown), (unknown), Karma Dacosta, (unknown), Hadassah Sade, J. Carl Barrett, Günter Schmidt, Ross Stewart	1
6	LBA49 Associations of ctDNA clearance (CL) during neoadjuvant Tx with pathological response and event-free survival (EFS) in pts with resectable NSCLC (R-NSCLC): Expanded analyses from AEGEAN 2024 ·Annals of Oncology ·Martin Reck, Davina Gale, Zhou Zhu, David Harpole, Janis M. Taube, (unknown), (unknown), Maximilian J. Hochmair, KY Lee, Yoshitsugu Horio, László Urbán, (unknown), Bivas Biswas, (unknown), Zsuzsanna Szalai, Ross Stewart, Zhongwu Lai, Darren Hodgson, Gary J. Doherty, John V. Heymach	15
7	Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study 2024 ·Molecular Cancer ·Mingchao Xie, (unknown), Jaime Rodriguez‐Canales, Johannes Zimmermann, Markus Schick, (unknown), Luis Paz‐Ares, Jonathan W. Goldman, Marina Chiara Garassino, Carl M. Gay, John V. Heymach, Haiyi Jiang, J. Carl Barrett, Ross Stewart, Zhongwu Lai, Lauren A. Byers, Charles M. Rudin, Yashaswi Shrestha	21
8	Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study 2023 ·Journal of Thoracic Oncology ·Myung‐Ju Ahn, Igor Bondarenko, Ewa Kalinka‐Warzocha, Byoung Chul Cho, Shunichi Sugawara, Gabriella Gálffy, Byoung Yong Shim, Nikolay Kislov, Rajnish Nagarkar, Ingel Demedts, Steven Gans, (unknown), Ross Stewart, Zhongwu Lai, Helen Mann, Xiaojin Shi, Maen Hussein	8
9	LBA59 Associations of ctDNA clearance and pathological response with neoadjuvant treatment in patients with resectable NSCLC from the phase III AEGEAN trial 2023 ·Annals of Oncology ·Martin Reck, Daniel P. Gale, David H. Harpole, Janis M. Taube, Tetsuya Mitsudomi, Maximilian J. Hochmair, Thomas Winder, Zhen Zhu, Zhongwu Lai, Ross Stewart, Darren Hodgson, Gary J. Doherty, John V. Heymach	23
10	379MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase Ib/II study 2023 ·Annals of Oncology ·Peter Schmid, Piotr J. Wysocki, X. Cynthia, Y.H. Park, (unknown), Simon Lord, Richard D. Baird, Catherine Prady, Kyung Hae Jung, Jamil Asselah, (unknown), Ross Stewart, (unknown), (unknown), Neelima Denduluri, Zbigniew Nowecki	25
11	Abstract PD11-08: PD11-08 Trastuzumab deruxtecan (T-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic hormone receptor-negative (HR−), HER2-low breast cancer: updated results from BEGONIA, a phase 1b/2 study 2023 ·Cancer Research ·Peter Schmid, Piotr J. Wysocki, (unknown), Jacek Jassem, Kyung Hae Jung, Simon Lord, (unknown), Ross Stewart, (unknown), (unknown), Zbigniew Nowecki	23
12	166MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from BEGONIA, a phase Ib/II study 2022 ·Annals of Oncology ·Patrick Schmid, (unknown), Piotr J. Wysocki, Jacek Jassem, X. Cynthia, (unknown), (unknown), Ross Stewart, (unknown), Ana T. Nunes, Zbigniew Nowecki	38
13	Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial breakdown → 2021 ·The Lancet Oncology ·Bradley J. Monk, Nicoletta Colombo, Amit M. Oza, Keiichi Fujiwara, Michael J. Birrer, Leslie M. Randall, Elena Poddubskaya, Giovanni Scambia, Yaroslav Shparyk, Myong Cheol Lim, (unknown), Joohyuk Sohn, Kan Yonemori, Ross Stewart, Xiaoxi Zhang, Julia Perkins Smith, Carlos Linn, Jonathan A. Ledermann	160
14	JAVELIN PARP medley: A phase Ib/II study of avelumab (anti–PD-L1) plus talazoparib in locally advanced or metastatic solid tumors 2018 ·Annals of Oncology ·Timothy A. Yap, J. Thaddeus Beck, Ross Stewart, (unknown), Colombe Chappey, Rossano Cesari, (unknown), Matt D. Galsky, David R. Wise	5
15	Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade 2017 ·Clinical Cancer Research ·Simon J. Dovedi, Eleanor J. Cheadle, (unknown), Edmund Poon, Michelle Morrow, Ross Stewart, Erik Yusko, Catherine Sanders, Marissa Vignali, Ryan Emerson, Harlan Robins, Robert W. Wilkinson, Jamie Honeychurch, Tim Illidge	263
16	The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment 2017 ·Journal for ImmunoTherapy of Cancer ·Edmund Poon, Stefanie Mullins, Amanda Watkins, Geoffrey S. Williams, Jens‐Oliver Koopmann, Gianfranco Di Genova, Marie Cumberbatch, Margaret H. Veldman-Jones, Shaun Grosskurth, Vasu R. Sah, Alwin G. Schuller, (unknown), Simon J. Dovedi, Paul D. Smith, Ross Stewart, Robert W. Wilkinson	59
17	PD-L1 Blockade for Cancer Treatment: MEDI4736 2015 ·Seminars in Oncology ·Ramy Ibrahim, Ross Stewart, Aiman Shalabi	76
18	Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade breakdown → 2014 ·Cancer Research ·Simon J. Dovedi, Amy L. Adlard, Grazyna Lipowska‐Bhalla, Conor McKenna, (unknown), Eleanor J. Cheadle, Ian J. Stratford, Edmund Poon, Michelle Morrow, Ross Stewart, Hazel Jones, Robert W. Wilkinson, Jamie Honeychurch, Tim Illidge	974
19	The anti-tumor immune response generated by radiation therapy may be limited by tumor cell adaptive resistance and can be circumvented by PD-L1 blockade 2014 ·Journal for ImmunoTherapy of Cancer ·Simon J. Dovedi, Amy L. Adlard, Grazyna Lipowska‐Bhalla, Conor McKenna, (unknown), (unknown), Ian J. Stratford, Edmund Poon, Michelle Morrow, Ross Stewart, Hazel Jones, Robert W. Wilkinson, Jamie Honeychurch, Tim Illidge	3
20	Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies 2009 ·Investigational New Drugs ·Gadi Gazit Bornstein, Christophe Quéva, Mohammad Tabrizi, Anne van Abbema, Carlos M. Chavez, Ping Wang, Orit Foord, (unknown), Naomi Laing, (unknown), Shenghua Wen, Larry L. Green, Xiaodong Yang, Carl I. Webster, Ross Stewart, David C. Blakey	20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact